Rapid test to identity myeloma kidney by measurement of serum free light chains

J. Campbell, A. Stride, M. Cobbold, Y. Wang, M. Goodall, S. Bonney, A. Chamba, T. Plant, Z. Afzal, R. Jefferis, M. Drayson

Research output: Contribution to journalMeeting abstractpeer-review

10 Citations (SciVal)


Monoclonal κ and λ immunoglobulin free light chains (FLC) in blood and urine are important biomarkers to determine if acute kidney injury (AKI) may be attributable to a plasma cell dyscrasia. Laboratory FLC tests offer the only means of detecting FLC and commonly have a slow turnaround time that delays early diagnosis of myeloma kidney and thus increases risk of kidney damage. We have developed a point-of-care (POC) lateral flow test that can rapidly measure FLC levels in blood or urine in 10 minutes. The POC test simultaneously quantitates κ and λ FLC levels using highly specific anti-κ and anti-λ FLC monoclonal antibodies (abstract also submitted). POC capture antibodies displayed no cross-reactivity to bound LC on whole immunoglobulin, the alternate LC type, or other human proteins, and had excellent sensitivity
Original languageEnglish
Pages (from-to)253-254
Number of pages2
JournalClinical Lymphoma, Myeloma and Leukemia
Publication statusPublished - 1 Apr 2013


  • immunoglobulin
  • monoclonal antibody
  • antigen
  • protein
  • antibody
  • myeloma
  • serum
  • kidney
  • light chain
  • identity
  • workshop
  • rapid test
  • human
  • urine
  • patient
  • blood
  • kidney injury
  • risk
  • early diagnosis
  • clinical practice
  • turnaround time
  • laboratory
  • plasma cell dyscrasia
  • cross reaction
  • competitive inhibition
  • donor
  • acute kidney failure


Dive into the research topics of 'Rapid test to identity myeloma kidney by measurement of serum free light chains'. Together they form a unique fingerprint.

Cite this